Key Highlights
• Liposomes are vesicles or sacs containing a volume of water surrounded by a membrane containing lipid (fat) molecules, mostly phospholipids. Basically, liposomes are bilayer vesicles that can encapsulate water-soluble drugs in their membranes. Liposomes are prepared by breaking down biofilms by sonication. The properties of liposomes such as multifunctionality, biodegradability, hypoallergenicity, and similarity to biological organisms are important in continued efforts to develop liposomal drug release. Types of liposomes are multilamellar, small monolamellate, large monolamellate and cochlear.
• The market size of the worldwide Liposomes Industry surpassed USD XX billion in 2022, and by 2032, it is projected to reach USD XX billion, boosting at a CAGR of XX%.
• In July 2020, Crode International, Plc acquired Avanti Polar Lipids, Inc., which will expand the lipid supply chain for next-generation drugs.
• The main reason for the growth of the liposome drug delivery market is the increasing need for effective and efficient treatment due to the increasing incidence of chronic diseases such as cancer, blood, diabetes and fungal diseases, while the development of liposome-based drug delivery systems. Some advantages for other distribution systems. Therefore, drugs are encapsulated within liposomes for best results. For example, according to research papers published by Liu Peng et al. In February 2022, liposomes have better properties than drug delivery systems such as sustained release, prolonged or controlled release, prevent degradation and clearance of drugs, higher, healing effect etc. Good curative effect, less toxic and side effects, it is the first choice for drug manufacturers. Therefore, increasing demand for therapeutic drugs amid the increasing incidence of chronic disease worldwide is expected to drive the growth of the liposomal delivery system market. For example, according to the latest data from the International Diabetes Federation in December 2021, there will be approximately 537 million adults aged 20 to 79 years with diabetes worldwide in 2021, and this number should reach 643 million 783 million by 2030. . This will increase the demand for diabetes drugs by 2045, thus enabling the growth of the market.
Scope of the Industry Profile
Key Players
• Acrotech Biopharma, Inc. (US)
• Astellas Pharma, Inc. (Japan)
• Avanti Polar Lipids, Inc. (US)
• Celsion, Inc. (US)
• Creative Biolabs (US)
• Encapsula NanoSciences LLC (US)
• Fudan-Zhangjiang (China)
• Galen Limited (UK)
• Ipsen Pharma (France)
• Luye Pharma Group (China)
Segmentation
By Technology
• Stealth Liposome Technology
• NonPEGylated Liposome Technology
• DepoFoam Liposome Technology
By Distribution Channel
• Retail Sales
• Academic & Research Laboratories
• Biopharmaceutical Companies
• Clinical Research Organizations
• Hospital Pharmacies
• Other Channels
By Type
• Doxorubicin Liposomes
• Amphotericin B Liposomes
• Paclitaxel Liposomes
• Cytarabine Liposomes
• Irinotecan Liposomes
• Cisplatin Liposomes
• Other Liposomes
By Application
• Drug Delivery
• Cancer
• Fungal Infection
• Viral & Parasite Infection
• Other Applications
What to Expect from Industry Profile
1. Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the Liposomes market in the world.
2. Use the PORTER’s Five Forces analysis to determine the competitive intensity and therefore market attractiveness of the Global Liposomes market.
3. Leading company profiles reveal details of key Liposomes market players’ global operations, strategies, financial performance & their recent developments.
4. Add weight to presentations and pitches by understanding the future growth prospects of the Global Liposomes market with forecast for decade by both market share (%) & revenue (USD Million).
Recent Development
• In June 2022, Endo Ventures Limited (EVL), a subsidiary of Endo International plc, acquired the clinical-stage private pharmaceutical company Taiwan Liposome Co., Ltd. signed an agreement with (TLC) will market TLC's research product, TLC599. TLC599 is an injectable drug in development stage 3 for the treatment of osteoarthritic knee pain.
• In January 2022, Pfizer and Acuitas Therapeutics signed a development and options agreement in which Pfizer will have the option to license Acuitas' lipid nanoparticle (LNP) technology for use of up to 10 Enhancements of the vaccine. or treatment.
• In June 2018, Virpax İlaç A.Ş. partnered with LipoCure to manufacture liposomes and develop pain management products.
• In March 2020, Fujifilm Corporation announced a plan for product development and process improvement with existing partners, its current line of business.
• In July 2020, Crode International, Plc acquired Avanti Polar Lipids, Inc., which will expand the lipid supply chain for next-generation drugs
Segment Insights
By Technology
Stealth liposome technology is increasingly in demand due to its superior ability to improve drug delivery. Technology that encapsulates therapeutic agents into latent liposomes (lipid nanoparticles with a protective PEG (polyethylene glycol) coating) prolongs blood circulation, reduces the risk of infection, and helps release a drug that targets cells or tissues. This advance has improved medicine by allowing lower doses, fewer side effects, and better outcomes, especially useful in the treatment of cancer, blood, infectious and chronic diseases. Therefore, increasing awareness of its ability to improve clinical outcomes is increasing the demand for covert liposome technology in clinical and therapeutic applications
By Type
The demand for doxorubicin liposomes is increasing due to its important role in increasing the efficacy and safety of cancer treatment. Doxorubicin is a potent antibiotic packaged in liposomes to form liposomes of doxorubicin. The formulation allows the drug to be transported to tumor cells, reducing damage to healthy tissue and reducing side effects. The growth of self-awareness and precision medicine has led to greater use of technology as it can improve treatment outcomes and patients' quality of life. Controlling the release and duration of the drug in liposomes increases its bioavailability and allows more drug to reach the tumor, making doxorubicin liposomes an effective anti-cancer strategy.
Regional Insights
North America is expected to lead the liposomal delivery market due to the high disease prevalence in the region, increasing aging population, strong medical conditions and some important markets in the region. For example, according to the Globocan 2020 report, North America reported an estimated 2.6 million new cancer cases in 2020 and is expected to increase to 3.5 million new cancer cases in the region by 2040. Therefore, the growing demand for cancer drugs in the region is expected to drive the growth of the education market in the North American region. In North America, the US should have a significant share of the academic market due to its many chronic diseases, strong medical and research fields. For example, according to the American Cancer Society's 2022 report, it is estimated that more than 1.9 million new cases of cancer will occur in the United States in 2022, and approximately 609,360 people will be diagnosed with cancer. Also, according to the same source, cancer is the second leading cause of death in the United States and therefore the high demand for advanced treatments in the country should have a positive impact on the development of business research in the country.
1 INTRODUCTION
1.1 Study Objectives
1.2 Market Definitions
1.2.1 Inclusions & Exclusions
1.2.2 Region: Inclusions & Exclusions
1.2.3 Study Scope
1.2.3.1 Markets Covered
1.2.3.2 Regional Scope
1.2.3.3 Years Considered
1.2.4 Currency Considered
1.2.5 Limitations
1.2.6 Summary Of Report (Chapter Wise Summary)
2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary & Primary Research
2.1.2 Secondary Data
2.1.2.1 Secondary Sources
2.1.3 Primary Data
2.1.3.1 Primary Sources
2.2 Market Breakdown & Data Triangulation
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Research Assumptions & Limitations
2.4.1 Assumptions
2.4.2 Limitations
3 EXECUTIVE SUMMARY
4 ACROSS THE GLOBE
4.1 Upcoming Attractive Market Opportunities
4.2 Country Wise Market Growth
4.3 Segment Wise Market Growth
5 MARKET OVERVIEW
5.1 Market Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.2 Restraints
5.2.3 Opportunities
5.2.4 Challenges
5.3 PORTOR’S Five Forces Analysis
5.3.1 Threat of New Entrants
5.3.2 Threat of Substitutes
5.3.3 Bargaining Power of Suppliers
5.3.4 Bargaining Power of Buyers
5.3.5 Intensity of Competitive Rivalry
5.4 Market Premium insights (Enterprise license)
5.4.1 Case Study Analysis
5.4.2 Country Wise Import & Export Data (If
Applicable)
5.4.3 Regulatory Bodies & Authorization
Across the Globe
5.4.4 Key Conferences & Events: 2022 &
2023
5.4.5 Top Patents for The Market: 2022
6 LIPOSOME MARKET OVERVIEW, BY
TECHNOLOGY
6.1 Global Market Revenue & Share Analysis, By Technology
6.1.1 Stealth Liposome Technology
6.1.2 NonPEGylated Liposome Technology
6.1.3 DepoFoam Liposome Technology
6.2 Global Market Revenue & Share Analysis, 2018 – 2022
6.3 Global Market Revenue & Share Forecast Analysis, 2023 –
2032
6.4 Key Takeaways
7 LIPOSOME MARKET OVERVIEW, BY
DISTRIBUTION CHANNEL
7.1 Global Market Revenue & Share Analysis, By Distribution
Channel
7.1.1 Retail Sales
7.1.2 Academic & Research Laboratories
7.1.3 Biopharmaceutical Companies
7.1.4 Clinical Research Organizations
7.1.5 Hospital Pharmacies
7.1.6 Other Channels
7.2 Global Market Revenue & Share Analysis, 2018 – 2022
7.3 Global Market Revenue & Share Forecast Analysis, 2023 –
2032
7.4 Key Takeaways
8 LIPOSOME MARKET OVERVIEW, BY TYPE
8.1 Global Market Revenue & Share Analysis, By Type
8.1.1 Doxorubicin Liposomes
8.1.2 Amphotericin B Liposomes
8.1.3 Paclitaxel Liposomes
8.1.4 Cytarabine Liposomes
8.1.5 Irinotecan Liposomes
8.1.6 Cisplatin Liposomes
8.1.7 Other Liposomes
8.2 Global Market Revenue & Share Analysis, 2018 – 2022
8.3 Global Market Revenue & Share Forecast Analysis, 2023 –
2032
8.4 Key Takeaways
9 LIPOSOME MARKET
OVERVIEW, BY APPLICATION
9.1 Global Market Revenue & Share Analysis, By Application
9.1.1 Drug Delivery
9.1.2 Cancer
9.1.3 Fungal Infection
9.1.4 Viral & Parasite Infection
9.1.5 Other Applications
9.2 Global Market Revenue & Share Analysis, 2018 – 2022
9.3 Global Market Revenue & Share Forecast Analysis, 2023 –
2032
9.4 Key Takeaways
10 LIPOSOME MARKET OVERVIEW, BY REGION
10.1 Global Market Revenue & Share Analysis, By Region
10.1.1 North America
10.1.2 Europe
10.1.3 Asia Pacific
10.1.4 Middle East & Africa
10.1.5 South America
10.2 Global Market Revenue & Share Analysis, 2018 – 2022
10.3 Global Market Revenue & Share Forecast Analysis, 2023 –
2032
10.4 Key Takeaways
11 NORTH AMERICA MARKET
ANALYSIS
11.1 North America Market Revenue & Share Analysis, By
Technology
11.2 North America Market Revenue & Share Analysis, By
Distribution Channel
11.3 North America Market Revenue & Share Analysis, By Type
11.4 North America Market Revenue & Share Analysis, By
Application
11.5 North America Market Revenue & Share Analysis, By Country
11.5.1 US
11.5.2 Canada
11.5.3 Mexico
11.6 Key Takeaways
12 EUROPE MARKET ANALYSIS
12.1 Europe Market Revenue & Share Analysis, By Technology
12.2 Europe Market Revenue & Share Analysis, By Distribution
Channel
12.3 Europe Market Revenue & Share Analysis, By Type
12.4 Europe Market Revenue & Share Analysis, By Application
12.5 Europe Market Revenue & Share Analysis, By Country
12.5.1 UK
12.5.2 Italy
12.5.3 Spain
12.5.4 Germany
12.5.5 France
12.5.6 Rest of Europe
12.6 Key Takeaways
13 ASIA PACIFIC MARKET ANALYSIS
13.1 APAC Market Revenue & Share Analysis, By Technology
13.2 APAC Market Revenue & Share Analysis, By Distribution
Channel
13.3 APAC Market Revenue & Share Analysis, By Type
13.4 APAC Market Revenue & Share Analysis, By Application
13.5 APAC Market Revenue & Share Analysis, By Country
13.5.1 China
13.5.2 Japan
13.5.3 India
13.5.4 South Korea
13.5.5 Rest of APAC
13.6 Key Takeaways
14 MIDDLE EAST & AFRICA MARKET
ANALYSIS
14.1 MEA Market Revenue & Share Analysis, By Technology
14.2 MEA Market Revenue & Share Analysis, By Distribution
Channel
14.3 MEA Market Revenue & Share Analysis, By Type
14.4 MEA Market Revenue & Share Analysis, By Application
14.5 MEA Market Revenue & Share Analysis, By Country
14.5.1 GCC
14.5.2 South Africa
14.5.3 Rest of MEA
14.6 Key Takeaways
15 SOUTH AMERICA MARKET ANALYSIS
15.1 SA Market Revenue & Share Analysis, By Technology
15.2 SA Market Revenue & Share Analysis, By Distribution
Channel
15.3 SA Market Revenue & Share Analysis, By Type
15.4 SA Market Revenue & Share Analysis, By Application
15.5 SA Market Revenue & Share Analysis, By Country
15.5.1 Brazil
15.5.2 Argentina
15.5.3 Rest of SA
15.6 Key Takeaways
16 COMPETITIVE SCENARIO
16.1 Overview
16.2 Key Players Market Share Analysis
16.3 Recent Developments & Product Launches
16.4 Mergers & Acquisitions
16.5 Partnerships, Agreements & Collaborations
17 COMPANY PROFILES
17.1 Overview
17.2 Key players
17.2.1 Acrotech Biopharma, Inc. (US)
17.2.1.1 Business Overview
17.2.1.2 Product Offered
17.2.1.3 Financial Insights
17.2.1.4 Strategic Developments
17.2.1.4.1 New Product Launches
17.2.1.4.2 Agreements & Collaborations
17.2.1.5 Business Aspects (NOISE Analysis)
17.2.1.5.1 Key Strengths
17.2.1.5.2 Opportunities
17.2.1.5.3 Weaknesses & Competitive Threats
17.2.1.5.4 Needs & Improvements
17.2.2 Astellas Pharma, Inc. (Japan)
17.2.3 Avanti Polar Lipids, Inc. (US)
17.2.4 Celsion, Inc. (US)
17.2.5 Creative Biolabs (US)
17.2.6 Encapsula NanoSciences LLC (US)
17.2.7 Fudan-Zhangjiang (China)
17.2.8 Galen Limited (UK)
17.2.9 Ipsen Pharma (France)
17.2.10 Luye Pharma Group (China)
18 DISCLAIMER
19 APPENDIX
